AR013070A1 - HYDROXAMATE-DERIVED COMPOUNDS INVERTED AS MATRIX METALOPROTEASE INHIBITORS, METALOPROTEASE INHIBITORS, AND DETNF-ALPHA INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE OF SUCH MEDIUM PREPARATIONS - Google Patents

HYDROXAMATE-DERIVED COMPOUNDS INVERTED AS MATRIX METALOPROTEASE INHIBITORS, METALOPROTEASE INHIBITORS, AND DETNF-ALPHA INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE OF SUCH MEDIUM PREPARATIONS

Info

Publication number
AR013070A1
AR013070A1 ARP980100842A ARP980100842A AR013070A1 AR 013070 A1 AR013070 A1 AR 013070A1 AR P980100842 A ARP980100842 A AR P980100842A AR P980100842 A ARP980100842 A AR P980100842A AR 013070 A1 AR013070 A1 AR 013070A1
Authority
AR
Argentina
Prior art keywords
inhibitors
metaloprotease
direct bond
defined below
heterocyclylene
Prior art date
Application number
ARP980100842A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR013070A1 publication Critical patent/AR013070A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Detergent Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una familia de compuestos que tienen la estructura general de la formula (I), en donde W, R1, R2, R3, R4, R5, R6, son como se define más adelante. Seproveen también composiciones farmacéuticas conteniendo dichos compuestos. Dichos compuestosinhiben las actividades de una o más de las metaloproteasasde matriz y se reconocen como que son de beneficio terapéutico en una o más patologías donde está desregulada la actividad de las MMP. El compuesto dondeW es un grupo ácido hidroxámico invértico de la formula (II), donde R1 es formula (III) en donde A1 es alquileno, alquenileno, alquinileno,cicloalquileno, cicloalquenileno, arileno, heterociclileno, heteroarileno, o un enlace directo; A2 es C(O)NR7, NR7C(O), SO2NR7, NR7SO2, NR7, S, SO, SO2, O,C(O), C(O)O, OC(O), o un enlace directo, en donde R7 es como se define a continuacion; A3 es alquileno, alquenileno, alquinileno, cicloalquileno,cicloalquenileno, arileno, heterociclileno, heteroarileno, o un enlace directo; A4 es alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo,heterociclilo, heteroarilo, arilo, NR8R9,OR8, o hidrogeno, en donde R8 y R9 son como se define a continuacion; R2 es formula (IV), en donde D1 es alquileno,alquenileno, alquinileno, cicloalquileno, cicloalquenileno, heterociclileno, NR10(O)C, NR10, S, SO, SO2, O, O(O)C, o un enlace directo, en donde R10 escomo se define a continuacion; D2 es S, SO, SO2, O, C(O), C(O)O, OC(O), C(O)NR11, NR11C(O), NR11, o un enlacedirecto, en donde R11 es como se definea continuacion; D3 es alquileno, alquenileno, alquinileno, cicloalquileno, cicloalquenileno, heterociclileno, S, SO, SO2, O, C(O), C(O)O, OC(O), C(O)NR12,NR12C(O), SO12NR12, NR12SO2, NR12, o un enlace directo, en donde R12 es como se define a continuacion; D4 es alquilo, alquenilo, alquinilo,A family of compounds having the general structure of formula (I), wherein W, R1, R2, R3, R4, R5, R6, are as defined below. Pharmaceutical compositions containing such compounds are also provided. Said compounds inhibit the activities of one or more of the matrix metalloproteases and are recognized as being of therapeutic benefit in one or more pathologies where the activity of MMPs is dysregulated. The compound where W is an inertic hydroxamic acid group of formula (II), where R1 is formula (III) where A1 is alkylene, alkenylene, alkynylene, cycloalkylene, arylene, heterocyclylene, heteroarylene, or a direct bond; A2 is C (O) NR7, NR7C (O), SO2NR7, NR7SO2, NR7, S, SO, SO2, O, C (O), C (O) O, OC (O), or a direct bond, where R7 is as defined below; A3 is alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, arylene, heterocyclylene, heteroarylene, or a direct bond; A4 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, aryl, NR8R9, OR8, or hydrogen, where R8 and R9 are as defined below; R2 is formula (IV), where D1 is alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, heterocyclylene, NR10 (O) C, NR10, S, SO, SO2, O, O (O) C, or a direct bond, where R10 is as defined below; D2 is S, SO, SO2, O, C (O), C (O) O, OC (O), C (O) NR11, NR11C (O), NR11, or a direct link, where R11 is as defined continuation; D3 is alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, heterocyclylene, S, SO, SO2, O, C (O), C (O) O, OC (O), C (O) NR12, NR12C (O), SO12NR12 , NR12SO2, NR12, or a direct bond, where R12 is as defined below; D4 is alkyl, alkenyl, alkynyl,

ARP980100842A 1997-02-26 1998-02-25 HYDROXAMATE-DERIVED COMPOUNDS INVERTED AS MATRIX METALOPROTEASE INHIBITORS, METALOPROTEASE INHIBITORS, AND DETNF-ALPHA INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE OF SUCH MEDIUM PREPARATIONS AR013070A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3911297P 1997-02-26 1997-02-26

Publications (1)

Publication Number Publication Date
AR013070A1 true AR013070A1 (en) 2000-12-13

Family

ID=21903750

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100842A AR013070A1 (en) 1997-02-26 1998-02-25 HYDROXAMATE-DERIVED COMPOUNDS INVERTED AS MATRIX METALOPROTEASE INHIBITORS, METALOPROTEASE INHIBITORS, AND DETNF-ALPHA INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE OF SUCH MEDIUM PREPARATIONS

Country Status (16)

Country Link
EP (1) EP1019386A1 (en)
JP (1) JP2001513767A (en)
KR (1) KR20000075681A (en)
AP (1) AP9901631A0 (en)
AR (1) AR013070A1 (en)
AU (1) AU6822398A (en)
BR (1) BR9807763A (en)
CA (1) CA2281664A1 (en)
HR (1) HRP980096A2 (en)
IS (1) IS5159A (en)
NO (1) NO994103L (en)
PE (1) PE59199A1 (en)
PL (1) PL335378A1 (en)
TR (1) TR199902063T2 (en)
WO (1) WO1998038179A1 (en)
ZA (1) ZA981532B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
DE69917221T2 (en) 1998-02-07 2005-05-04 Vernalis (Oxford) Ltd., Abington ANTIBACTERIAL AGENTS
AU5582899A (en) * 1998-08-26 2000-03-21 Glaxo Group Limited Formamides as therapeutic agents
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
WO2000012466A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
JP2003081838A (en) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd Glucosamine preparation
EP1476168A2 (en) 2002-02-04 2004-11-17 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
JP2006517216A (en) * 2003-02-11 2006-07-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pharmaceutical composition based on an anticholinergic agent and a TACE inhibitor
EP1993583A4 (en) * 2006-02-09 2010-06-23 Burnham Inst Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
ES2357682T3 (en) 2008-03-25 2011-04-28 Affectis Pharmaceuticals Ag ANNOUNCERS OF P2X7R NOVEDOSOS AND ITS USE.
SI2243772T1 (en) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
PT2699242T (en) 2011-04-19 2018-01-22 Alfama Inc Carbon monoxide releasing molecules and uses thereof
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP6134710B2 (en) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． Ruthenium monoxide releasing molecules and uses thereof
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CZ290145B6 (en) * 1994-01-20 2002-06-12 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
CZ292617B6 (en) * 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors and pharmaceutical preparation containing thereof

Also Published As

Publication number Publication date
NO994103L (en) 1999-10-25
AP9901631A0 (en) 1999-09-30
WO1998038179A1 (en) 1998-09-03
AU6822398A (en) 1998-09-18
TR199902063T2 (en) 1999-12-21
JP2001513767A (en) 2001-09-04
KR20000075681A (en) 2000-12-26
EP1019386A1 (en) 2000-07-19
PL335378A1 (en) 2000-04-25
ZA981532B (en) 1999-08-24
BR9807763A (en) 2000-02-22
CA2281664A1 (en) 1998-09-03
HRP980096A2 (en) 1998-12-31
IS5159A (en) 1999-08-20
NO994103D0 (en) 1999-08-25
PE59199A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
AR013070A1 (en) HYDROXAMATE-DERIVED COMPOUNDS INVERTED AS MATRIX METALOPROTEASE INHIBITORS, METALOPROTEASE INHIBITORS, AND DETNF-ALPHA INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE OF SUCH MEDIUM PREPARATIONS
TNSN00200A1 (en) NEW BIARYL ETHER DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE
TR200201509T2 (en) Pharmaceutically active benzazole derivatives.
NZ511394A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
SV1998000008A (en) SULFAMIDE-METALOPROTEASE INHIBITORS. REF. RAN 4070 \ 114
BR9806296B1 (en) sulfonic acid compounds, mixture, composition and use thereof.
ATE212981T1 (en) 1-ACYL-4-ALIPHATIC AMINOPIPERIDINE COMPOUNDS
HUP0100472A2 (en) Novel amines as pharmaceutical agents
AR029216A1 (en) NON-PEPTIDIC INHIBITING COMPOUNDS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES; PHARMACEUTICAL COMPOSITION AND TREATMENT PROCEDURE
AR008861A1 (en) ARALQUILO AND ARALQUILEDENO LETAMIC AND IMIDA LACTAM COMPOUNDS, INTERMEDIARY COMPOUNDS FOR YOUR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HUP0003731A2 (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
PE20020354A1 (en) HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
HUP0500573A2 (en) Triphenyl-ethylene derivatives as selective estrogen receptor modulators and pharmaceutical compositions containing the same
MA26727A1 (en) NOVEL PYRIMIDINE DERIVATIVES OF SORBITOL DEHYDROGENASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
DK0494819T3 (en) New phenylimidazolidines, their preparation, use as pharmaceuticals and pharmaceutical compositions containing them
TR200100075T2 (en) Pharmaceutical compositions containing 2-quinolone
KR900014361A (en) Nicotinic acid derivatives and pharmaceutical compositions containing them
ES2108027T3 (en) NEW TRICYCLIC COMPOUNDS CONTAINING AMINO AND NITRO, USEFUL AS ACE INHIBITORS.
ES2177058T3 (en) ETER PIPERIDINYLAMINOMETIL TRIFLUOROMETIL CYCLES COMPOUNDS AS AN SUBGONIST OF THE SUBSTANCE P.
BR0111678A (en) Medicinal compositions containing propenone derivatives
ES2178451T3 (en) DERIVATIVES OF BENZOXADIAZOLES, BENZOTIADIAZOLES, BENZOTRIAZOLES AND QUINOXALINAS.
AR008621A1 (en) A COMPOUND DERIVED FROM SUCCINIC AMINE, A PROCEDURE FOR CARRYING OUT ITS PREPARATION AND A PHARMACEUTICAL COMPOSITION INCLUDING SUCH A COMPOSITION
PE20011183A1 (en) METABOLITES AGONISTS / ANTAGONISTS OF ESTROGEN
ATE93863T1 (en) ENZYME INHIBITING AMINO ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, COMPOSITIONS THEREOF AND THEIR USE.